Needham analyst Ami Fadia maintained a Buy rating on Neumora Therapeutics, Inc. today and set a price target of $6.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Ami Fadia’s rating is based on the promising preclinical data for Neumora Therapeutics, Inc.’s obesity drug, NMRA-215. The drug demonstrated significant weight loss effects, achieving approximately 19% weight loss with incretin-like induction at Day 7 and up to 26% weight loss when combined with semaglutide. Additionally, NMRA-215 showed similar weight loss results to semaglutide but with a statistically greater preservation of lean mass.
The potential of NMRA-215 to be a best-in-class treatment, along with the company’s strategic focus on developing novel mechanisms, supports the Buy rating. The anticipated clinical program set to begin in the first quarter of 2026, with proof-of-concept data expected by the end of 2026, further strengthens the investment outlook for Neumora Therapeutics.
In another report released on October 24, H.C. Wainwright also reiterated a Buy rating on the stock with a $18.00 price target.